---
title: "Rhythm Pharma | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 51.3 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264214985.md"
published_at: "2025-11-04T12:09:56.000Z"
---

# Rhythm Pharma | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 51.3 M

Revenue: As of FY2025 Q3, the actual value is USD 51.3 M, beating the estimate of USD 50.71 M.

EPS: As of FY2025 Q3, the actual value is USD -0.82, missing the estimate of USD -0.7167.

EBIT: As of FY2025 Q3, the actual value is USD -61.72 M.

### Segment Revenue

-   **Net Product Revenue**: Rhythm Pharmaceuticals reported net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million for the third quarter of 2025, marking an increase from $33.3 million in the third quarter of 2024.

### Operational Metrics

-   **Net Loss**: The net loss attributable to common stockholders was - $54.3 million for the third quarter of 2025, compared to - $45.0 million for the third quarter of 2024.
-   **R&D Expenses**: Research and development expenses were $46.0 million in the third quarter of 2025, up from $37.9 million in the third quarter of 2024.
-   **SG&A Expenses**: Selling, general, and administrative expenses were $52.4 million for the third quarter of 2025, compared to $35.4 million for the third quarter of 2024.

### Cash Flow

-   **Cash Position**: As of September 30, 2025, cash, cash equivalents, and short-term investments totaled approximately $416.1 million, compared to $320.6 million as of December 31, 2024.

### Unique Metrics

-   **Revenue Impact**: Revenue for the third quarter of 2025 was reduced by approximately $3.2 million due to a change in the company’s price estimate associated with its early-access program in France.

### Outlook / Guidance

-   Rhythm Pharmaceuticals anticipates approximately $295 million to $315 million in Non-GAAP Operating Expenses for the year ending December 31, 2025. The company expects its cash, cash equivalents, and short-term investments as of September 30, 2025, will be sufficient to fund planned operations for at least 24 months.

### Related Stocks

- [RYTM.US - Rhythm Pharma](https://longbridge.com/en/quote/RYTM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025 | Rhythm Pharmaceuticals (RYTM) has issued strong preliminary revenue guidance for its drug IMCIVREE, projecting approxima | [Link](https://longbridge.com/en/news/272952447.md) |
| Titan Company's Consolidated Profit Rises in Fiscal Q3 | Titan Company's Consolidated Profit Rises in Fiscal Q3 | [Link](https://longbridge.com/en/news/275539283.md) |
| Shootin' the Bull about cash, basis, and a need for more money | Shootin' the Bull about cash, basis, and a need for more money | [Link](https://longbridge.com/en/news/275653722.md) |
| Biocon Q3 consol net profit 1.44 bln rupees | Biocon Q3 consol net profit 1.44 bln rupees | [Link](https://longbridge.com/en/news/275805052.md) |
| Canada's CAE beats Q3 adjusted EPS estimates | Canada's CAE reported fiscal Q3 results with revenue slightly rising and adjusted EPS of C$0.34, beating estimates of C$ | [Link](https://longbridge.com/en/news/275809290.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
